Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Other Accumulated Expenses (2024 - 2025)

Historic Other Accumulated Expenses for ARS Pharmaceuticals (SPRY) over the last 2 years, with Q3 2025 value amounting to $3.1 million.

  • ARS Pharmaceuticals' Other Accumulated Expenses changed N/A to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year change of. This contributed to the annual value of $570000.0 for FY2024, which is N/A changed from last year.
  • ARS Pharmaceuticals' Other Accumulated Expenses amounted to $3.1 million in Q3 2025.
  • In the past 5 years, ARS Pharmaceuticals' Other Accumulated Expenses ranged from a high of $3.1 million in Q3 2025 and a low of $570000.0 during Q4 2024